Dyscovry

Business Services · Canada · 11-50 Employees

View Company Info for Free

Overview

Headquarters

Toronto, Ontario, Canada

Revenue

<$5 Million

Industry

Business Services Research & Development
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1

About Dyscovry

Dyscovry Science Ltd is an innovative Toronto-based biotechnology company conducting research to establish a world-leading position in the development of fungal- and plant-derived therapeutics through its proven drug discovery and development processes, its growing intellectual property portfolio, and regulatory and manufacturing expertise. Dyscovry is led by an experienced team with government, university and private partnerships focussing on biosynthesis of psilocybin and investigating a quantifiable anti-inflammatory effect of psychedelics believed to be mediated through 5-HT2A activation and how this relationship pertains to disorders that affect the large intestine. We are are focused on indications such as Irritable Bowel Syndrome (IBS) that inflict suffering on a double digit percentage of the entire human global population. This suffering includes the physiological symptoms but also the secondary psychological symptoms from living with this disease.Explore more
Popular SearchesDyscovry Science LtdSIC Code 87,873NAICS Code 54,541Show more

Is Dyscovry your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Recommended Actions

Compare Similar Companies to Dyscovry

Compare insights from companies similar to Dyscovry, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.

Company Name

Revenue

Number of Employees

Type

Funding

Founded In

Top Executive

Dyscovry

<$5M
11-50
Private
-
-
N/A
$9.9M
1-10
Private
-
2008
JB
Jean-Louis BrochuCommunications Director, Intellectual Property
$5.9M
11-50
Private
-
1996
Brady Clark, Chief Executive Officer & Founder at Sussex Research Laboratories
Brady ClarkCEO & Founder
<$5M
11-50
Private
-
2019
RK
Rasika KulkarniAdministration Manager, Research
<$5M
11-50
Private
-
-
<$5M
1-10
Private
-
2008
MP
Marc PourrierVice President, Operations
<$5M
1-10
Private
-
2001
MA
Marie ArnoldPersonal Assistant
Illustration of an envelope

Company Profile Activity

i

Among all Business Services companies

Low Activity

High Activity

Activity Insights

Dyscovry is experiencing very low activity levels compared to other companies in the Business Services sector.

What does this means?

Dyscovry is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Dyscovry.

Dyscovry Tech Stack

A closer look at the technologies used by Dyscovry

Dyscovry News & Media

Read more news

Top Business Services Companies

Frequently Asked Questions Regarding Dyscovry

What is Dyscovry's official website?
Dyscovry's official website is www.dyscovry.com
What is Dyscovry's Revenue?
Dyscovry's revenue is <$5 Million
What is Dyscovry's SIC code?
Dyscovry's SIC: 87,873
What is Dyscovry's NAICS code?
Dyscovry's NAICS: 54,541
How many employees does Dyscovry have?
Dyscovry has 11-50 employees
What industry does Dyscovry belong to?
Dyscovry is in the industry of: Business Services, Research & Development
What is Dyscovry competition?
Dyscovry top competitors include: IonsGate Preclinical Services, Iricor, Cerebrasol, NanoMedicines Innovation Network
What companies has Dyscovry acquired?
Dyscovry has acquired the companies: Dyscovry, NUGL
What technology does Dyscovry use?
Some of the popular technologies that Dyscovry uses are: GoCentral, GoDaddy DNS
What does Dyscovry do?

Dyscovry Science Ltd is an innovative Toronto-based biotechnology company conducting research to establish a world-leading position in the development of fungal- and plant-derived therapeutics through its proven drug discovery and development processes, its growing intellectual property portfolio, and regulatory and manufacturing expertise. Dyscovr... y is led by an experienced team with government, university and private partnerships focussing on biosynthesis of psilocybin and investigating a quantifiable anti-inflammatory effect of psychedelics believed to be mediated through 5-HT2A activation and how this relationship pertains to disorders that affect the large intestine. We are are focused on indications such as Irritable Bowel Syndrome (IBS) that inflict suffering on a double digit percentage of the entire human global population. This suffering includes the physiological symptoms but also the secondary psychological symptoms from living with this disease.Read More

Is Dyscovry a public company?
Dyscovry is private company therefore does not currently have an official ticker symbol
See more information about Dyscovry

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.